Interim results from a midstage trial for the plant-derived coronavirus vaccine developed by Medicago and being tested with GlaxoSmithKline's pandemic adjuvant showed neutralizing antibody responses were higher tenfold after two doses in vaccinated participants versus recovering COVID-19 patients, both in adults age 18 to 64 and the elderly, those age 65 and older.
Medicago, GSK report on plant-derived COVID-19 vaccine
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.